Concerning the newer antihyperglycemic agents, only glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors seem to be useful in patients with NAFLD or NASH. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.